Trevi Therapeutics Inc. (TRVI)
6.05
-0.17 (-2.73%)
At close: Apr 04, 2025, 3:59 PM
6.19
2.23%
After-hours: Apr 04, 2025, 05:32 PM EDT
-2.73% (1D)
| Bid | 5.7 |
| Market Cap | 585.41M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.47 |
| PE Ratio (ttm) | -12.88 |
| Forward PE | -8.25 |
| Analyst | Buy |
| Ask | 6.5 |
| Volume | 1,304,614 |
| Avg. Volume (20D) | 1,987,950 |
| Open | 5.95 |
| Previous Close | 6.22 |
| Day's Range | 5.79 - 6.11 |
| 52-Week Range | 2.30 - 7.39 |
| Beta | 0.41 |
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo P...
Industry Biotechnology
Sector Healthcare
IPO Date May 7, 2019
Employees 26
Stock Exchange NASDAQ
Ticker Symbol TRVI
Analyst Forecast
According to 9 analyst ratings, the average rating for TRVI stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 230.31% from the latest price.
Stock Forecasts3 weeks ago
+41.16%
Trevi Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
3 months ago
+15.83%
Trevi Therapeutics shares are trading higher after HC Wainwright & Co. reiterated a Buy rating on the stock and raised its price target from $6 to $7.5.
